United Therapeutics (Germany) Analysis
| UTH Stock | EUR 347.90 1.30 0.37% |
United Therapeutics is undervalued with Real Value of 87.15 and Hype Value of 0.0. The main objective of United Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what United Therapeutics is worth, separate from its market price. There are two main types of United Therapeutics' stock analysis: fundamental analysis and technical analysis. Fundamental analysis focuses on the financial and economic factors that affect United Therapeutics' performance, such as revenue growth, earnings, and financial stability. Technical analysis, on the other hand, focuses on the price and volume data of United Therapeutics' stock to identify patterns and trends that may indicate its future price movements.
The United Therapeutics stock is traded in Germany on Frankfurt Exchange, with the market opening at 08:00:00 and closing at 22:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in Germany. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and United Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
United |
United Stock Analysis Notes
About 98.0% of the company outstanding shares are owned by institutional investors. The book value of United Therapeutics was at this time reported as 104.2. The company has Price/Earnings To Growth (PEG) ratio of 1.0. United Therapeutics recorded earning per share (EPS) of 13.25. The entity had not issued any dividends in recent years. The firm had 2:1 split on the 23rd of September 2009. United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people. For more information please call the company at 301 608 9292 or visit https://www.unither.com.United Therapeutics Investment Alerts
| Over 98.0% of the company outstanding shares are owned by institutional investors |
United Market Capitalization
The company currently falls under 'Large-Cap' category with a current market capitalization of 10.75 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate United Therapeutics's market, we take the total number of its shares issued and multiply it by United Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.United Profitablity
United Therapeutics' profitability indicators refer to fundamental financial ratios that showcase United Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, United Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, United Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of United Therapeutics' profitability requires more research than a typical breakdown of United Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of 0.38 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.51 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.51. Technical Drivers
As of the 6th of January, United Therapeutics has the Coefficient Of Variation of 1480.55, risk adjusted performance of 0.0611, and Semi Deviation of 2.25. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of United Therapeutics, as well as the relationship between them. Please validate United Therapeutics maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to decide if United Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 347.9 per share.United Therapeutics Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. United Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for United Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
United Therapeutics Outstanding Bonds
United Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. United Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most United bonds can be classified according to their maturity, which is the date when United Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| UNITED TECHNOLOGIES P Corp BondUS913017CR85 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CP20 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CW70 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CY37 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017CX53 | View | |
| Dana 575 percent Corp BondUS235822AB96 | View | |
| UNITED TECHNOLOGIES P Corp BondUS913017DD80 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View |
United Therapeutics Predictive Daily Indicators
United Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of United Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
United Therapeutics Forecast Models
United Therapeutics' time-series forecasting models are one of many United Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary United Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About United Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how United Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling United shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as United Therapeutics. By using and applying United Stock analysis, traders can create a robust methodology for identifying United entry and exit points for their positions.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland. UTD THERAP operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 860 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding United Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Earnings Calls Now
Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges |
| All Next | Launch Module |
Complementary Tools for United Stock analysis
When running United Therapeutics' price analysis, check to measure United Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy United Therapeutics is operating at the current time. Most of United Therapeutics' value examination focuses on studying past and present price action to predict the probability of United Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move United Therapeutics' price. Additionally, you may evaluate how the addition of United Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |